GHRH Hormone Drives Cancer-Like Changes in Human Prostate Cells
Background
The growth hormone-releasing hormone (GHRH) is a crucial hypothalamic peptide that stimulates the release of growth hormone (GH) from the pituitary gland, playing a vital role in normal growth and metabolism. However, emerging research suggests that GHRH and its receptors are also expressed in various cancers, including prostate cancer, where they may act as autocrine/paracrine growth factors, promoting tumor progression. This study addresses the critical knowledge gap regarding whether GHRH directly induces tumorigenic transformation in non-cancerous human prostatic epithelial cells.
Results
The study demonstrated that exposure to GHRH significantly promoted several aspects of tumorigenic transformation in RWPE-1 cells. Cell proliferation was markedly increased by 43% at the highest GHRH concentration compared to untreated controls (p<0.01). Furthermore, GHRH treatment led to a 2.8-fold increase in cellular migration and a 3.5-fold increase in invasive potential, indicating enhanced metastatic capabilities. Molecular analysis revealed an upregulation of pro-tumorigenic genes like c-Myc and VEGF (a protein that promotes new blood vessel growth), alongside a downregulation of tumor suppressor genes. The most compelling finding was a 4.0-fold increase in anchorage-independent colony formation, a definitive in vitro indicator of cellular transformation, in GHRH-treated cells compared to controls (p<0.001).
Why It Matters
This research provides strong evidence that GHRH can directly induce tumorigenic characteristics in normal human prostate cells, suggesting it plays a more direct role in prostate cancer initiation and progression than previously understood. This finding is crucial because it identifies GHRH and its receptors as potential novel therapeutic targets for prostate cancer treatment. Targeting the GHRH pathway could lead to the development of new anti-cancer drugs or diagnostic markers for early intervention. Future steps should involve in vivo studies using animal models to confirm these findings and eventually progress towards Phase II human trials for GHRH receptor antagonists.